Neurotech International (ASX:NTI), developer of medical solutions in the neuroscience space, has announced the clinical trial for Mente Autism has progressed as planned with investigators now approaching the end of the 12-week therapy session for the initial cohort of subjects.
The trial, which is being independently conducted by the Carrick Institute in the US, aims to investigate Mente Autism as a therapy for children aged between 3 and 12 years on the autism spectrum. Subjects are being progressively onboarded to Mente Autism to commence 12 weeks of at home therapy, and the initial subjects will start to conclude this therapy shortly.
Based on the advice of lead investigator Professor Frederick Carrick, the preliminary findings of the study are expected to be ready for presentation at the University of Cambridge world conference on mental health disorders in September this year.
“The randomised placebo controlled trial of the Mente Autism device is currently ongoing in Orlando, Florida. Subjects with diagnosed Autism Spectrum Disorder from throughout the United States have been randomised into a treatment group and a sham group. These groups have been entered into a 12-week at home therapy investigation using the Mente Autism device. Investigators report that they are approaching the end of the 12-week therapy session for the initial cohort of subjects,” said Professor Carrick.